Liver Metastases clinical trials at UC Cancer

• Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

  open to eligible people ages 18 years and up

  The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

  at UCSF

Last updated: October 5, 2021